

Supplementary Table 1 Ustekinumab's role in Postoperative Crohn's disease: Summary of efficacy and outcomes from recent research

Ref.	Study Type	Country	Patient Characteristics	Biologic Agents	Treatment Protocol	Sample Size	Disease	Efficacy Results
Anthony Buisson <i>et al</i> [1], 2021	Retrospective Multicenter Study	Europe	Postoperative CD patients who underwent resection and anastomosis.	UST, Azathioprine	Comparison of UST and Azathioprine effectiveness	63	CD	Endoscopic POR rates of 20.8% in the UST group vs. 42.5% in the Azathioprine group (p = 0.066). Severe endoscopic POR: 16.9% vs. 27.9% (p = 0.24).
Henit Yanai <i>et al</i> [2], 2022	Retrospective Multicenter Study	Europe	297 postoperative CD patients,	TNF- α , VDZ, UST	Comparing TNF- α , VDZ, UST for	297	CD	Approximately 60% successfully prevented ePOR

Míriam Mañosa <i>et al</i> [3], 2023	Retrospective Observational Study	Spain	with 65.7% having prior anti-TNF therapy.	UST, VDZ	postoperative recurrence prevention	65	CD	within 1 year; no significant difference in ePOR risk between anti-TNF and other groups.
			CD patients from the ENEIDA registry who received surgery and started UST or VDZ within three months postoperation		Prescription within three months post-anastomosis			Cumulative probability of clinical POR at 12 months: 32% (UST) and 30% (VDZ).

			for	POR					
			prevention.						
Fabio Salvatore Macaluso <i>et al</i> [4], 2023	Real-World Study	Italy	Adult patients who underwent endoscopy 6-12 months postoperatively to confirm POR.	CD UST	Evaluating treatment effectiveness post-UST initiation	44	CD	Successful endoscopic results in 50% of patients, with 75% showing severe POR (Rutgeerts score ≥3). Clinical success rate: 72.7%.	
Ferdinando D'Amico <i>et al</i> [5], 2023	Single-Center Observational Study	Italy	141 surgical CD patients; impact of biological therapy on	ADA, IFX, UST, VDZ	Early biological therapy outcomes	141	CD	Higher endoscopic recurrence rates in untreated patients	

Furkan U Ertem et al[6], 2024	Cross-Sectional Study	USA	endoscopic recurrence rates. CD patients undergoing ileocecal resection from 2009 to 2019 with postoperative follow-up.	UST, VDZ	Comparing UST vs. VDZ postoperative efficacy	98	CD	compared to treated (80.8% vs. 45.2%, P < .0001). Early postoperative recurrence rates: 5% (UST) vs. 6% (VDZ). Median drug exposure: 51 months (UST) vs. 30 months (VDZ).
-------------------------------------	--------------------------	-----	---	----------	---	----	----	---

UST: Ustekinumab; CD: Crohn's disease; POR: Postoperative recurrence.

REFERENCES

- 1 **Buisson A**, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira

B, Peyrin-Biroulet L, Vuitton L, USTEK Post-Op study group, . Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. *United European Gastroenterol J* 2021; **9**: 552-560 [PMID: 33951350 DOI: 10.1002/ueg2.12068]

- 2 **Yanai H**, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Bar-Gil Shitrit A, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Calviño Suárez C, Weissshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Surís G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broytman Y, Amir Barak H, Avni-Biron I, Ollech JE, Dotan I, Aharoni Golan M. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. *J Crohns Colitis* 2022; **16**: 1882-1892 [PMID: 35895074 DOI: 10.1093/ecco-jcc/jjac100]
- 3 **Mañosa M**, Fernández-Clotet A, Nos P, Martín-Arranz MD, Manceñido N, Carbajo A, Hinojosa E, Hernández-Camba A, Muñoz-Pérez R, Boscá-Watts M, Calvo M, Sierra-Ausín M, Sánchez-Rodríguez E, Barreiro-de Acosta M, Núñez-Alonso A, Zabana Y, Márquez L, Gisbert JP, Guardiola J, Sáinz E, Delgado-Guillena P, Busquets D, van Domselaar M, Girona E, Lorente R, Casas-Deza D, Huguet JM, Maestro S, Cabello MJ, Castro J, Iborra M, Cañete F, Calafat M, Domènech E, ENEIDA

registry by GETECCU, . Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry. *Dig Liver Dis* 2023; **55**: 46-52 [PMID: 35948459 DOI: 10.1016/j.dld.2022.07.013]

- 4 **Macaluso FS**, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, Orlando A, Sicilian Network for Inflammatory Bowel Disease (SN-IBD), . Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease. *J Gastroenterol Hepatol* 2023; **38**: 1503-1509 [PMID: 37148148 DOI: 10.1111/jgh.16208]
- 5 **D'Amico F**, Tasopoulou O, Fiorino G, Zilli A, Furfaro F, Allocca M, Sileri P, Spinelli A, Peyrin-Biroulet L, Danese S. Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. *Inflamm Bowel Dis* 2023; **29**: 539-547 [PMID: 35640113 DOI: 10.1093/ibd/izac110]
- 6 **Ertem FU**, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, Johnston E, Barrie A, Harrison J, Dueker JM, Hartman D, Binion DG. Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data. *Inflamm Bowel Dis* 2024 : izae137 [pii] [PMID: 38953641 DOI: 10.1093/ibd/izae137]